KR20230132450A - 항trpv6 단일 클론 항체 및 그 응용 - Google Patents

항trpv6 단일 클론 항체 및 그 응용 Download PDF

Info

Publication number
KR20230132450A
KR20230132450A KR1020237022218A KR20237022218A KR20230132450A KR 20230132450 A KR20230132450 A KR 20230132450A KR 1020237022218 A KR1020237022218 A KR 1020237022218A KR 20237022218 A KR20237022218 A KR 20237022218A KR 20230132450 A KR20230132450 A KR 20230132450A
Authority
KR
South Korea
Prior art keywords
antibody
seq
antigen
binding fragment
trpv6
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020237022218A
Other languages
English (en)
Korean (ko)
Inventor
바오후아 로버트 황
웨이 탄
종보 왕
웨이 왕
Original Assignee
코히런트 바이오파마 (쑤저우), 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코히런트 바이오파마 (쑤저우), 리미티드 filed Critical 코히런트 바이오파마 (쑤저우), 리미티드
Publication of KR20230132450A publication Critical patent/KR20230132450A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • G01N33/57484—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020237022218A 2021-01-15 2022-01-14 항trpv6 단일 클론 항체 및 그 응용 Withdrawn KR20230132450A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/072249 2021-01-15
CN2021072249 2021-01-15
CN202210029357.7 2022-01-11
CN202210029357 2022-01-11
PCT/CN2022/071976 WO2022152236A1 (zh) 2021-01-15 2022-01-14 抗trpv6单克隆抗体及其应用

Publications (1)

Publication Number Publication Date
KR20230132450A true KR20230132450A (ko) 2023-09-15

Family

ID=82447968

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237022218A Withdrawn KR20230132450A (ko) 2021-01-15 2022-01-14 항trpv6 단일 클론 항체 및 그 응용

Country Status (8)

Country Link
US (1) US20260116965A1 (https=)
EP (1) EP4293044A4 (https=)
JP (1) JP2024505430A (https=)
KR (1) KR20230132450A (https=)
CN (1) CN116802277A (https=)
CA (1) CA3206472A1 (https=)
TW (1) TW202246332A (https=)
WO (1) WO2022152236A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022365387A1 (en) * 2021-10-14 2024-05-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies against extracellular epitopes of human trpv6 channel and their diagnostic and therapeutic uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1229386C (zh) * 2002-09-16 2005-11-30 上海新世界基因技术开发有限公司 具有抑癌功能的新的人蛋白及其编码序列
EP2445932B1 (en) * 2009-06-26 2018-02-28 Soricimed Biopharma Inc. Soricidin derived peptides and methods for the detection of trpv-6 cancers and drug delivery
CN105399798B (zh) * 2015-11-24 2019-11-08 广东药科大学 Trpc3抗原多肽和抗trpc3的单克隆抗体
AU2022365387A1 (en) * 2021-10-14 2024-05-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies against extracellular epitopes of human trpv6 channel and their diagnostic and therapeutic uses

Also Published As

Publication number Publication date
JP2024505430A (ja) 2024-02-06
CN116802277A (zh) 2023-09-22
TW202246332A (zh) 2022-12-01
CA3206472A1 (en) 2022-07-21
EP4293044A4 (en) 2025-05-28
US20260116965A1 (en) 2026-04-30
EP4293044A1 (en) 2023-12-20
WO2022152236A1 (zh) 2022-07-21

Similar Documents

Publication Publication Date Title
CA2855699C (en) Anti-human trop-2 antibody having an antitumor activity in vivo
US9823251B2 (en) Anti-Uroplakin II antibodies systems and methods
KR102056137B1 (ko) 암의 검출 방법
JPWO2008114733A1 (ja) 抗Ｃｌａｕｄｉｎ−４抗体
JPWO2003093317A1 (ja) ヒトインスリン様成長因子に対する抗体
CA2669731A1 (en) Anti-human dlk-1 antibody showing anti-tumor activity in vivo
JP2021046417A (ja) 抗Ａｇｇｒｕｓモノクローナル抗体、ＣＬＥＣ−２との結合に必要なＡｇｇｒｕｓの領域、及びＡｇｇｒｕｓ−ＣＬＥＣ‐２結合阻害剤のスクリーニング方法
CN113735971A (zh) 抗ck18蛋白单克隆抗体及其细胞株、制备方法和应用
KR102486507B1 (ko) 플렉틴-1 결합 항체 및 그의 용도
JP2019068805A (ja) 抗ヒトｃｌｃｐ１抗体とその用途
CN109627338B (zh) 一种新型抗人pd-l1抗体及其应用
KR20230132450A (ko) 항trpv6 단일 클론 항체 및 그 응용
KR20130135869A (ko) 항 단쇄 제4형 콜라겐 폴리펩타이드 항체 및 이를 포함하는 종양의 진단, 예방 또는 치료용 약제
WO1999060025A1 (fr) Anticorps recombines de gene
WO2014146487A1 (zh) 抗细胞表面异位表达的单克隆抗体及其制备方法和用途
CN111434686B (zh) 一种抗人pbx1单克隆抗体，其制备方法及其在复发性流产临床诊断中的用途
CN108467433B (zh) 抗Napsin A蛋白的单克隆抗体及其细胞株、制备方法和应用
CN106957367A (zh) 抗idh1 r132h抗体及其制备方法和用途
CN112724253B (zh) 抗人穹窿体蛋白的抗体及其应用
US20250092124A1 (en) Antibody molecule against growth and differentiation factor 15 and use thereof
HK40105295A (en) Anti-trpv6 monoclonal antibody and application thereof
RU2790326C2 (ru) Анти-сd3-антитело и молекула, содержащая это антитело
WO2025218662A1 (zh) 抗成纤维细胞生长因子受体2b的抗体及其用途
WO2024251260A1 (zh) 结合Nectin-4的抗体及其用途
WO2023184734A1 (zh) 一种抗hla-g1，-g2，-g5及hla-g6异构体分子的单克隆抗体及其用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202

WITB Written withdrawal of application
P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000